BlackRock Fund Advisors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

BlackRock Fund Advisors’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.12M	Buy	391,135 +54,363	+16%	+$728K	﹤0.01%	2921
2016 Q3	$4.88M	Buy	336,772 +22,794	+7%	+$324K	﹤0.01%	2856
2016 Q2	$3.77M	Buy	313,978 +59,952	+24%	+$963K	﹤0.01%	2967
2016 Q1	$4.74M	Sell	254,026 -7,690	-3%	-$127K	﹤0.01%	2775
2015 Q4	$5.62M	Buy	261,716 +6,551	+3%	+$138K	﹤0.01%	2781
2015 Q3	$4.32M	Sell	255,165 -2,711	-1%	-$67.4K	﹤0.01%	2873
2015 Q2	$9.67M	Buy	+257,876	New	+$8.32M	﹤0.01%	2522

Other funds holding CBMG

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock Fund Advisors's CBMG Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Cellular Biomedicine Group, Inc. (CBMG) stake by 16% in Q4 2016, buying an estimated $728K and bringing the position to 391,135 shares worth $5.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

BlackRock Fund Advisors first reported a position in CBMG in Q2 2015 and has held it in 7 quarters since. The position peaked at $9.67M in Q2 2015. 38 funds tracked by Wall St. Rank hold CBMG as of Q4 2016.

BlackRock Fund Advisors held 391,135 shares of Cellular Biomedicine Group, Inc. worth $5.12M as of Q4 2016.
BlackRock Fund Advisors bought 54,363 Cellular Biomedicine Group, Inc. shares in Q4 2016, an estimated $728K.
Cellular Biomedicine Group, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2921 holding.
BlackRock Fund Advisors first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and has held it in 7 quarters since.
BlackRock Fund Advisors's Cellular Biomedicine Group, Inc. position peaked at $9.67M in Q2 2015.
38 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.